Table Of Content

index Adolescence: depression, suicide and of Counselling (BAC), 115, 11 iberate self-harm in, 47-60 Bupropion, 86, 89, 92, 94 lepression, and culture, 38-9 Buspirone, 89, 95 Amitripyline, 153 A3 hippocampal neurones, 72-4 Amoxapine, 90, 168 -AMP response element binding protein Anderson IM: Meta-analytical studies on CREB), 64-72 intidepressants, 161-78 arbamazepine , 179, 181-2, 183, 185-6, nvulsants as mood stabilisers, 181-7 188 nts (ADs), 164-5 hildhood Experience of Care and Abuse 2nd generation ADs, 165, CECA), 21 hinese Health Questionnaire, 36 tion (ADM), 103-12 CISR see Revised clinical interview schedule ie of withdrawal from, 151-2 CISR meta-analytical studies on, Citalopram, 91, 169 ,l assification of £ d, epression, 3—/ -8 tunction, 86-94 lassification, disability and the public health agenda: Lewis G, Araya R, 3-15 linical management (CM), 103-12 1 depression overl]a p lomipramine, 87, 88, 90, 202 . ~ Lewis G o-morbidity, 5 Sexual Experience Scale ochrane Review, 115-1 ognitive behavioural therapy (CBT 4-5, 115-32, 136-8, 139, 141, model, 135 treatment programmes, 52 Baldwin DS: Depression and sexual ognitive therapy for depression: Scott J, dysfunction, 81-99 101-13 Barkham M, Hardy GE Counselling and omposite International Diagnostic interpersonal therapies for depression: Interview (CIDI), 6, 37 towards securing an evidence-base, omputer-based and written self-help 15-32 treatments for depression, 133-44 ck Depression Inventory (BDI), 104, onsultations (professional) for common 17-21, 125-6, 129 mental disorder, lay attitudes to, 207-19 Beck Hopelessness Scale (BHS), 139 ontinuation and maintenance therapy in ck’s cognitive theory of depression, depression: Paykel ES, 145-59 01-2 OPE system, for self-help, 137 eck’s depressive cognitive triad, 18-19 ounselling and interpersonal therapies for sSehavioural family therapy, 102 depression: towards securing an evidence- volar affective disorder, 179-90, 187 base: Barkham M, Hardy GE, 115-32 Brain-derived neurotrophic factor (BDNF), ross-cultural psychiatry, the relevance of: a 67, 69-77 critique, 34-5 British Association cultural factors and international for Behavioural and Cognitive epidemiology: Patel V, 33-45 Psychotherapies (BABCP), 119 Cut-off scores for caseness, 36 for Psychopharmacology (BAP), 197 Cyproheptadine, 95 British Medical Bulletin 2001; 57: 225-228 The British Council 2001 Depression Deliberate self-harm (DSH), 54-8 Ferrier IN: Developments in mood Dentate gyrus (DG), 74-5 stabilisers, 17 Depression and Fluoxetine, 5 — emerging insights from neurobiology: 164, 169, 17 Vaidya VA, Duman RS, 61-70 Fluvoxamine, 89, 90, 91, 169-71, 175 public health, 12-13 Fresh start experiences and remission from sexual dysfunction: Baldwin DS, depression, 19 81-99 suicide and deliberate self-harm in adolescence: Harrington RC, 47-60 G-protein receptor, 63 Desipramine, 87, 202 Gabapentin, 184 Developments in mood stabilisers: Ferrier Gender and culture on depression, 38-9 IN, 179-92 Gene modification and depression, 66-7 Dexamethasone Suppression Test (DST), General Health Questionnaire (GHQ), 36, 104 139 Dexamphetamine, 95 Global burden of disease (GBD), 8 Diagnosis of depression, 35-8 Guidelines in primary care, treatment Diagnostic and Statistical Manual of Mental delivery and, 193-206 Disorders (DSM-III), 10, 83 (DSM-IV), 4, 48, 82-83, 195 Hamilton Rating Scales for Depression Differential diagnosis of other difficulties, (HAMD), 5, 88, 104, 194 48-9 Hampshire Depression Project, 198-200 Disability Adjusted Life Years (DALYs), 7-9 Hardy GE see Barkham M Disability, classification, and the public Harrington RC: Depression, suicide and health agenda, 3-15 deliberate self-harm in adolescence, 47-60 Dothiepin, 170, 202 Harris TO: Recent developments in Doxepin, 87, 92 understanding the psychosocial aspects of Duman RS see Vaidya VA depression, 17-32 Dysfunctional Attitudes Scale (DAS), 139 Health Action Zones, 25 Health Technology Assessment (HTA programme, 117 Effect size (ES), 118, 120, 121, 125, 169 Hippocampal CA3, 72-4 Effectiveness of computer-administered self- Humiliation/entrapment (H/E) and help materials, 136-8 depressive onset, 18-20 Effectiveness of written self-help materials, 135-6 Elderly patients and new antidepressants, Imipramine, 53, 87, 90, 150, 164, 170, 202 174 Indian Psychiatric Survey Schedule, 37 Electroconvulsive seizure (ECS), 74-5 Inducible cAMP early repressor (ICER) Electroconvulsive therapy (ECT), 148, 149, proteins, 69 187-8 Interactive voice response (IVR) system, in adolescents, 53 137 Endogenous depression, 20-1 International Classification of Mental and Epidemiological Catchment Area Study, Behavioural Disorders (ICD), 34 9-10 ICD-10 (diagnostic manual), 4, 82 Epidemiology International Pathways to Care Study, 39 (international), cultural factors and, Interpersonal psychotherapy (IPT), 24, 102, 33-45 £05, 123, 125,127, 12-3; 54 and sexual dysfunction, 83-4 Interpersonal therapies and counselling for Evidence-base, towards securing an: depression: towards securing an evidence- counselling and interpersonal therapies for base, 115-32 depression, 115-32 Ischaemic heart disease (IHD), 9 SO REEL GET IE MEME 28 TET TE INI EE COOLED BEE SS ENTIRE RA A REE TSE TOE LE EAE II OLY EE LT EIDE AIOE EEE IE PSE SEE SEI ESP IESW ISE DEAS PLPT ETE ELS! SBOE TERETE PT EOE IN British Medical Bulletin 2001;57 Kendrick T see Peveler R Newer antidepressants (NA), 166, 167 elderly patients and, 174 Non-directive counselling (ND¢ 119-20 ader MH, Cowen PJ: Preface, 1-2 Nortriptyline, 53, 87, 202 179, 181, 183-4, 185-6 Number needed to harm (NNH), 162 to professional consultations Number needed to treat (NNT , 162, 163, mental disorder: 1 169, 173 ) sociological perspective: Pill R, Prior L, Wood F, 207-19 ay attitudes to professional consultations Odds ratio (OR), 162, 167, 171 for common mental disorder, 207-19 Older antidrepressants (OA), 164, 165, ewis G, Araya R: Classification, disability 166. 167 public health agenda, 3-15 OPCS National Survey of Psychiatric nts, 10 Morbidity. 6,12 2] 10 ind Difficulties Schedule (LEDS). 11 Outcome research, 103-8 Lithium, 148, 151, 179-81 of continuation and maintainence FLiitthibuam -trs icvclic combieen ationsd,e> $185 1 t\h erapy, 14‘ 5- Lofepramine, 164, 165, 167-8, 175, 202 Overcoming depression course, 141-3 Maintenance and continuation therapy in Paroxetine, 87, 90, 91, 92, 169 dFe pression, 145-59 Patel V: Cultural factors and international Management of depression, and culture, epidemiology, 33-45 Maprotiline, 164, 165, 170, 202 Paykel ES: Continuation and maintenance Mediators of effect, 110 therapy in depression, 145-59 Messenger cascades, regulation of Peveler R, Kendrick T: Treatment delivery intracellular, 62-66 and guidelines in primary care, 193-206 Meta-analytical studies on new Phenelzine, 90 antidepressants: Anderson IM, 161-78 Phosphodiesterases (PDEs), 64 Methods for assessing depressive disorders, Pill R, Prior L, Wood F: Lay attitudes to » = professional consultations for common Mianserin, 95, 170, 202 mental disorder: a sociological perspective, Milnacipran, 88, 149, 166 207-19 Mirtazapine, 86, 88, 89, 92, 94, 164, 166, Predictors of response, 108-10 Preface: Lader MH, Cowen PJ, 1-2 Moclobemide, 86-88, 90, 92, 175 Primary care guidelines, treatment delivery Monoamine oxidase inhibitors (MAOIs) as 193-206 antidepressants, 86, 94, 145, 147-9, 151 Primary Care Psychiatric Questionnaire Mood stabilisers (PPQ), 36 developments in, 151, 179-92 rior L see Pill R issues relating to prescribing Psycho-education and psychological anticonvulsants, 185- treatments, 188 Psychodynamic-interpersonal therapy (PDIPT), 123-5, 127-9 National Institute of Mental Health (NIMH) Psychosocial aspects of depression, recent Treatment of Depression Collaborative developments in understanding the, 17-32 Research Program, 101, 103, 104, Psychosocial interventions, 52-3 106, 109 Public health agenda, classification and Nefazodone, 86, 90, 92, 93, 165, 169, 182 disability, 3-15 Neostigmine, 95 Neurobiology, depression — emerging insights from, 61-70 Randomised control trials (RCTs), 147, Neurotoxicity with lithium, 180 161, 164, 167, 175, 181, 182, 184 British Medical Bulletin 2001;57 Depression Rapid Eye Movement (REM) sleep latency, mental disorder, 207-19 104 St John’s wort, 166 Rebound phenomena, 186 Stigma of depression — a personal view: Reboxetine, 86 Wolpert L, 221-4 Recent developments in understanding the Structural plasticity and depression, 72-6 psychosocial aspects of depression: Harris Suicide TO, 17-32 and antidepressants, 174-5 Receptor activation, 64 depression and deliberate self-harm in Relative effect size (ES), 162 adolescence, 47-60 Reversible inhibitors of monoamine oxidase rate, effects on, 187 A (RIMAs), 165, 168-9, 174, 175 Sure Start, 25 Revised Clinical Interview Schedule (CISR), 6,12, 37, 220 Risk difference (RD), 162, 163, 169 TCAs, 199 Risk ratio (RR), 162, 163, 169 Teratogenesis, 186 Thyroid hormones and bipolar disorder, 188 Schedules for Clinical Assessment in Tiagabine, 184 Neuropsychiatry (SCAN), 5-6, 37 Topiramate, 184 Scott J: Cognitive therapy for depression, Transcranial magnetic stimulation (TMS), 101-13 188 Screening questionnaires, 36- Trazodone, 87, 170, 202 Second Sheffield Psychotherapy Project Treatment delivery and guidelines in primary SPP2);. 122) 423-7, .129 care: Peveler R, Kendrick T, 193-206 Self Reporting Questionnaire (SRQ), 36 Tricyclic antidepressants (TCAs), 53, 86, Self-harm (deliberate), depression, and 88, 90, 94, 145, 147, 149, 150-1, 161, suicide in adolescence, 47-60 163-5, 169-74 Self-help treatments for depression, written TCA2) — 2nd generation, 167 and computer-based 133-44 Serotonin and noradrenaline re-uptake inhibitors (SNRIs), 161, 164, 168, 172-4, Vaidya VA, Duman RS: Depression — 176 emerging insights from neurobiology, Serotonin specific re-uptake inhibitors 61-70 (SSRIs), 5 53, 86, 88-90, 94, 95, 147, 149, Valproate semi-sodium (‘Depakote’), 181 151, 161, 164-7 , 169-72, 182, 202 Valproate, 179, 181, 182-3, Sertraline, 89-93, 169, 171, 175 Venlafaxine, 87, 88, 90, 92, 166, 169 Sexual dysfunction, depression and, 81-99 methods of assessing, 94-5 Whitfield G see Williams C treatment, 95-6 Williams C, Whitfield G: Written and Sexual Function Questionnaire, 89, 95 computer-based self-help treatments for Shona Symptom Questionnaire in depression, 133-44 Zimbabwe, 36 Wolpert L: Stigma of depression — a personal Short-term psychodynamic psychotherapy view, 221-4 (STPDT)> 123 Wood F see Pill R Sildenafil (Viagra), 81, 95-6 Written and computer-based self-help Social Adjustment Scale, 88 treatments for depression: Williams C, Social capital, 20 Whitfield G, 133-44 Socio-economic status and depression, 11-12 Sociological perspective: lay attitudes to professional consultations for common Yohimbine, 95 I SEITE MAELO RY RENEE SAE NE ERLE SS EA ST ELLIER ALA E ESAS TCE ETI AN ESE EARLE TEE SNE ATES SEE ERIE EEG EEE DEIR NE BANE REN SAYER OTTO British Medical Bulletin 2001;57 err po puree